pravastatin has been researched along with Coronary Disease in 415 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 154 (37.11) | 18.2507 |
| 2000's | 225 (54.22) | 29.6817 |
| 2010's | 35 (8.43) | 24.3611 |
| 2020's | 1 (0.24) | 2.80 |
| Authors | Studies |
|---|---|
| Hoang, T; Kim, J | 1 |
| Blankenberg, S; Elliott, J; Espinoza, D; Glasziou, PP; Hague, W; Keech, AC; Nestel, PJ; Robledo, KP; Simes, J; Stewart, RA; Sullivan, DR; Tonkin, AM; White, HD; Zeller, T | 1 |
| Kim, DH; Lux, E; Orkaby, AR; Rich, MW; Sun, R; Wei, LJ | 1 |
| Baimbridge, C; Barzilay, JI; Basile, JN; Davis, BR; Henriquez, MA; Huml, A; Kopyt, N; Louis, GT; Pressel, SL; Rahman, M; Rosendorff, C; Sastrasinh, S; Stanford, C | 1 |
| Baimbridge, C; Ciocon, JO; Cuyjet, AB; Dart, RA; Davis, BR; Einhorn, PT; Ford, CE; Gordon, D; Hartney, TJ; Holtzman, J; Julian Haywood, L; Margolis, KL; Mathis, DE; Oparil, S; Probstfield, JL; Simpson, LM; Stokes, JD; Wiegmann, TB; Williamson, JD | 1 |
| Briggs, A; Buckley, BM; Comber, H; de Craen, AJ; Ford, I; Jukema, JW; Kearney, PM; Lloyd, SM; Marchbank, L; Packard, CJ; Perry, I; Sattar, N; Stott, DJ; Trompet, S; Westendorp, RG | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Fournier, M; Nestel, PJ; Simes, J; Sullivan, DR; Tonkin, AM; White, HD | 1 |
| Blankenberg, S; Colquhoun, D; Hunt, D; Keech, AC; Mann, K; Nestel, P; Simes, J; Stewart, R; Sullivan, D; Thompson, P; Tonkin, A; West, M; White, HD | 1 |
| Barnes, EH; Blankenberg, S; Colquhoun, DM; Hunt, D; Keech, AC; Marschner, IC; Nestel, P; Simes, J; Stewart, RA; Sullivan, DR; Thompson, P; Tonkin, A; West, M; White, HD; Zeller, T | 1 |
| Assendelft, WJ; Blom, HJ; Blom, JW; de Craen, AJ; de Ruijter, W; Drewes, YM; Ford, I; Gussekloo, J; Poortvliet, RK; Sattar, N; Stott, DJ; Westendorp, RG; Wouter Jukema, J | 1 |
| Blankenberg, S; Colquhoun, D; Funke-Kaiser, A; Hunt, D; Mann, K; Simes, J; Sullivan, D; Sydow, K; Tonkin, AM; West, M; White, H; Zeller, T | 1 |
| Hori, E; Itoh, T; Kajikuri, J; Kikuchi, C; Kimura, K; Matsunaga, T; Nagami, C | 1 |
| Matsuyama, Y; Ohashi, Y; Shinozaki, T | 1 |
| Kobayashi, F; Kuroki, M | 1 |
| Akao, H; Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Kajinami, K; Packard, C; Polisecki, E; Robertson, M; Schaefer, EJ; Trompet, S | 1 |
| Albers, M; Baumeister, SE; Kroemer, HK; Meyer zu Schwabedissen, HE; Nauck, M; Rimmbach, C; Siegmund, W; Völzke, H; Wallaschofski, H | 1 |
| Hua, L; Li, Y; Liu, H; Wang, D; Xiong, X; Zhao, H | 1 |
| Deedwania, PC; Fayyad, RS; Laskey, RE; Stone, PH; Wilson, DJ | 1 |
| de Craen, AJ; Lingsma, HF; Mooijaart, SP; Nieboer, D; Richard, E; Steyerberg, EW; van Leeuwen, N | 1 |
| Koh, KK | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Ishikawa, T; Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Barnes, EH; Colquhoun, D; Keech, A; Nestel, P; Pollicino, C; Simes, J; Söderberg, S; Tonkin, AM; Yallop, J | 1 |
| Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Cheng, JL; Cui, J; Dong, M; Jiang, SL; Li, QS; Li, X; Liu, C; Peng, CH; Tian, Y | 1 |
| Arnett, DK; Boerwinkle, E; Cheng, S; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI; Maitland-van der Zee, AH; Peters, BJ | 1 |
| Buckley, BM; Ford, I; Jukema, JW; Lichtenstein, AH; Matthan, NR; Packard, C; Resteghini, N; Robertson, M; Schaefer, EJ; Shepherd, J | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H | 1 |
| Li, J; Li, ZQ; Pan, W; Wang, LF | 1 |
| Buckley, BM; de Craen, AJ; Ford, I; Hegele, RA; Jukema, JW; Packard, C; Peter, I; Polisecki, E; Robertson, M; Schaefer, EJ; Shepherd, J; Simon, JS; Westendorp, RG | 1 |
| Hennekens, C | 1 |
| Dunn, K; Einhorn, PT; Ford, CE; Gordon, DJ; Margolis, KL; Probstfield, JL; Simpson, LM; Williamson, JD | 1 |
| Arishiro, K; Hanafusa, T; Hoshiga, M; Ishihara, T; Kohbayashi, E; Miyazaki, N; Nakakoji, T; Negoro, N; Okabe, T | 1 |
| Blauw, GJ; Catanese, JJ; Devlin, JJ; Ford, I; Iakoubova, OA; Jukema, JW; Murphy, MB; Robertson, M; Rowland, CM; Shepherd, J; Tong, CH | 1 |
| Bryniarski, L; Ducobu, J; Farnier, M | 1 |
| Bell, KJ; Glasziou, P; Hayen, A; Irwig, L; Kirby, A | 1 |
| Cobbe, S; Ford, I; Logue, J; Macfarlane, P; Murray, HM; Packard, C; Sattar, N; Shepherd, J; Welsh, P | 1 |
| Bonovas, S; Nikolopoulos, G; Sitaras, NM | 1 |
| Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Hirahara, K; Mizuno, K; Mizutani, M; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Ichikawa, S; Ishikura, N; Kamiyama, K; Matsushima, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Buckley, BM; Catanese, JJ; de Craen, AJ; Devlin, JJ; Ford, I; Iakoubova, OA; Jukema, JW; Kirchgessner, TG; Louie, JZ; Packard, CJ; Rowland, CM; Sacks, FM; Sattar, N; Shiffman, D; Slagboom, PE; Stott, DJ; Trompet, S; Westendorp, RG | 1 |
| Gardberg, M; Kohonen, Ia; Lähdesmäki, J; Martikainen, MH | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Amore, C; Angelini, A; Baccante, G; Cuccurullo, F; di Castelnuovo, A; Di Febbo, C; Di Nisio, M; Donati, M; Iacoviello, L; Porreca, E | 1 |
| Irons, BK; MacLaughlin, EJ; McCall, K; Snella, KA; Villarreal, M | 1 |
| Mehta, JL; Singh, BK | 1 |
| Meadows, SE; Stevermer, JJ | 1 |
| Bernardi, G; Boccanelli, A; Fioretti, P; Morocutti, G; Pagano, A; Parma, A; Prati, F; Sommariva, L; Tomai, F | 1 |
| Koizumi, J; Mabuchi, H; Miyamoto, S; Origasa, H; Shimizu, M | 1 |
| Császár, A; Márk, L | 1 |
| Lavie, CJ; Mehra, MR; Milani, RV; Park, MH; Scott, RL; Solis, S; Uber, PA; Vivekananthan, K | 1 |
| Anderson, NE; Hankey, GJ; Hunt, D; Kirby, A; Simes, RJ; Tonkin, AM; Watson, JD; West, MJ; White, HD; Wonders, S | 1 |
| Blazing, MA; Duvall, WL; Guyton, JR; Saxena, S | 1 |
| Arai, H; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Tsuchiya, Y; Zhang, B | 1 |
| Aronov, DM; Bubnova, MG; Golubev, MA; Mel'kina, OE; Olfer'ev, AM; Perova, NV; Zhasminova, VG | 1 |
| Holme, I; Tonstad, S | 1 |
| Ferrières, J | 1 |
| Goldstein, MR | 2 |
| Traynor, K | 1 |
| Campos, H; Lee, SJ; Moye, LA; Sacks, FM | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Clark, LT | 1 |
| Faust, M | 1 |
| Mikhailidis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Baztán, JJ; Hornillos, M; Rodríguez-Mañas, L | 1 |
| Forder, P; Hague, W; Hunt, D; Simes, J; Tonkin, A | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Conraads, V | 1 |
| Arakawa, K; Iwashita, M; Kono, S; Matsushita, Y; Sasaki, J | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Lee, SJ; Sacks, FM | 1 |
| Cobbe, SM; Ford, I; Gaw, A; Haffner, SM; Isles, C; Macfarlane, PW; O'Reilly, DS; Packard, CJ; Sattar, N; Scherbakova, O; Shepherd, J | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA | 1 |
| Bruschke, AV; Hollaar, L; Mulder, HJ; Schalij, MJ; van der Laarse, A; Zwinderman, AH | 1 |
| Braund, PS; Caslake, MJ; Cheng, S; Freeman, DJ; Gaffney, D; McMahon, AD; Packard, CJ; Samani, NJ; Wilson, V | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| März, W | 2 |
| Shepherd, J | 4 |
| Backer, C; Crawford, SE; Mavroudis, C; Pahl, E; Rodgers, S; Seipelt, IM; Seipelt, RG | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Tellier, P | 1 |
| Agema, WR; Boer, JM; de Maat, MP; Feskens, EJ; Jukema, JW; Kastelein, JJ; Rabelink, TJ; van Boven, AJ; van der Wall, EE; Zwinderman, AH | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Cheung, BM; Kumana, CR; Lau, CP; Lauder, IJ | 1 |
| Watts, GF | 1 |
| Ehrenborg, E; Karpe, F; Ledmyr, H; Lithell, H; MacFarlane, PW; McMahon, AD; Neville, M; Nielsen, LB; Packard, CJ | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Ahmed, M; Griffiths, P | 1 |
| Jackson, G | 3 |
| Cheng, B; Qi, BL; Zhang, QH | 1 |
| Ford, I; Lowe, GD; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A | 1 |
| Byington, RP; Sacks, FM | 1 |
| Hegmann, T | 1 |
| Auer, J; Eber, B; Weber, T | 1 |
| Levenson, D | 1 |
| Awata, N; Kobayashi, T; Matsushita, Y; Sato, S | 1 |
| Cobbe, SM; Craven, T; Curhan, GC; Furberg, C; Isles, C; Pfeffer, MA; Sacks, FM; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| Asano, Y; Asanuma, H; Fujita, M; Hirata, A; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Minamino, T; Mori, H; Node, K; Ogai, A; Okuda, H; Sanada, S; Shinozaki, Y; Takashima, S; Tomoike, H | 1 |
| Cannon, CP; Ray, KK | 2 |
| Cobbe, SM; Ford, I; Isles, CG; Lorimer, AR; MacFarlane, PW; McKillop, JH; Packard, CJ; Shepherd, J | 2 |
| Rosenson, RS | 1 |
| Deedwania, PC | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Berg, AM; Kanter, KR; Mahle, WT; Vincent, RN | 1 |
| Cheng, TO | 1 |
| Colquhoun, DM; Heritier, SR; Kirby, AC; Nestel, PJ; Simes, RJ; Stewart, RA; Tonkin, AM; West, MJ; White, HD | 1 |
| Asselbergs, FW; Bakker, SJ; de Jong, PE; Geluk, CA; Hillege, HL; van Gilst, WH; Zijlstra, F | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Forouhi, NG; Sattar, N | 1 |
| Curtiss, FR | 1 |
| Cobbe, SM; Craven, T; Curhan, GC; Furberg, C; Isles, C; Packard, C; Pfeffer, MA; Sacks, FM; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| Auer, J; Eber, B; Lamm, G | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Anazawa, T; Furukawa, K; Kanmatsuse, K; Kawamata, H; Kushiro, T; Nagao, K; Sato, Y; Tachibana, E; Tani, S; Watanabe, I | 1 |
| Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A | 1 |
| Cogert, G; Hage, A; Hamilton, MA; Kobashigawa, JA; Laks, H; Marquez, A; Moriguchi, JD; Patel, J; Vassilakis, ME; Wener, L; Yeatman, L | 1 |
| Armstrong, DF; Chan, P; Eagle, KA; Fang, J; Goldberg, AD; Kline-Rogers, E; Mukherjee, D; Nallamothu, BK; Patel, A; Rubenfire, M; Tsai, TT | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Hingorani, A; Humphries, SE | 1 |
| Barnetson, RS; Pua, VS; Scolyer, RA | 1 |
| Rahman, M; Rashidi, A | 1 |
| Clearfield, M | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A | 1 |
| Plans-Rubió, P | 1 |
| Adams, V; Erbs, S; Goettsch, W; Hambrecht, R; Holtz, J; Krekler, M; Kuss, O; Lenk, K; Mohr, FW; Morawietz, H; Schubert, A; Schuler, G | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Einecke, D | 1 |
| Ajiki, W; Awata, N; Kobayashi, T; Sato, S | 1 |
| Campos, H; Catanese, JJ; Chokkalingam, AP; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Leong, DU; Lew, D; Louie, JZ; Luke, MM; Packard, CJ; Ploughman, LM; Rowland, CM; Sabatine, MS; Sacks, FM; Shaw, PM; Shepherd, J; Tong, CH; Tsuchihashi, Z; Young, BA; Zerba, KE | 1 |
| Calabresi, L; Sirtori, CR | 1 |
| Barron, TI; Bennett, K; Feely, J | 1 |
| Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Klungel, OH; Leiendecker-Foster, C; Maitland-van der Zee, AH; Miller, MB | 1 |
| Dimmeler, S; Spyridopoulos, I | 1 |
| Brouilette, SW; Ford, I; McMahon, AD; Moore, JS; Packard, CJ; Samani, NJ; Shepherd, J; Thompson, JR | 1 |
| Athyros, VG; Elisaf, M; Kakafika, A; Karagiannis, A; Mikhailidis, DP | 1 |
| Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D | 1 |
| Blauw, GJ; Bollen, EL; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; McConnachie, A; Murphy, MB; Murray, HM; Packard, CJ; Perry, IJ; Sattar, N; Shepherd, J; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RG | 1 |
| Gotto, AM | 5 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Chen, BL; Deng, S; Fan, L; He, YJ; Ozdemir, V; Peng, DD; Wang, A; Wang, LC; Xie, QY; Xie, W; Xu, LY; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Antikainen, M; Ehnholm, C; Hedman, M; Holmberg, C; Jauhiainen, M; Jokinen, E; Pahlman, R; Sundvall, J; Syvänne, M | 1 |
| Dagli, N; Karaca, I; Yavuzkir, M | 1 |
| Matsuyama, Y; Ohashi, Y; Tanaka, Y | 1 |
| Cobbe, SM; Ford, I; Macfarlane, PW; Murray, H; Packard, CJ; Shepherd, J | 1 |
| Domanski, MJ | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Braunwald, E; Campos, H; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Long, DU; Packard, CJ; Pfeffer, MA; Ploughman, L; Ranade, K; Sabatine, MS; Sacks, FM; Shepherd, J; Simonsen, KL; Tong, CH; Tsuchihashi, Z; Zerba, KE | 1 |
| Blake, GJ; Margey, R; McEvoy, JW | 1 |
| Kami, M; Tsubokura, M | 1 |
| Bansal, S; Blumenthal, RS; DeFilippis, AP | 1 |
| Arellano, AR; Braunwald, E; Campos, H; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Packard, CJ; Pfeffer, MA; Rowland, CM; Sabatine, MS; Sacks, FM; Shepherd, J; Shiffman, D; Tong, CH; White, TJ; Young, BA | 1 |
| Braunwald, E; Cannon, CP; Catanese, JJ; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Ranade, K; Rowland, CM; Sabatine, MS; Simonsen, KL; Tong, CH | 1 |
| MacDonald, TM; Murphy, MJ; Watson, AD; Wei, L | 1 |
| Liakishev, AA | 1 |
| Blauw, GJ; Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; McMahon, AD; Murphy, MB; Ordovas, JM; Packard, C; Peter, I; Polisecki, E; Robertson, M; Schaefer, EJ; Shepherd, J; Trompet, S; Westendorp, RG | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Jacobson, TA; Walker, DB | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Adachi, H; Imaizumi, T; Iwata, A; Matsunaga, A; Miura, S; Nishikawa, H; Noda, K; Saku, K; Shirai, K; Yanagi, D; Yoshinaga, K; Zhang, B | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Oliver, MF | 2 |
| Pedersen, TR | 2 |
| Mancini, GB | 1 |
| Gotto, AM; Jones, PH | 1 |
| Byington, RP; Furberg, CD; McGovern, ME; Park, JS; Pitt, B | 1 |
| Hung, J; Lacoste, L; Lam, JY; Letchacovski, G; Solymoss, CB; Waters, D | 1 |
| Chia, D; Cogert, GA; Johnson, JA; Katznelson, S; Kobashigawa, JA; Laks, H; Sabad, A; Terasaki, PI; Wang, XM; Yeatman, L | 1 |
| Schroeder, JS; Valantine, HA | 1 |
| Birkenhäger, JC; Ghanem, H; Jansen, H; Kuypers, JH | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Braun, P; May, E; Merz, M; Park, JW; Vermeltfoort, M | 1 |
| Hosoda, S; Kawai, C; Yui, Y | 1 |
| Bal, ET; Boerma, GJ; Bruschke, AV; Jansen, H; Jukema, JW; Lie, KI; Reiber, JH; van Boven, AJ; van Rappard, FM; Zwinderman, AH | 1 |
| Pirich, C; Sinzinger, H | 1 |
| Hina, K; Iwasaki, K; Kita, T; Kusachi, S; Nishiyama, O; Takaishi, A; Taniguchi, G; Yamasaki, S | 1 |
| Hirota, Y; Ishii, K; Ishimura, T; Kawamura, K; Kita, Y; Onaka, H; Tsuji, R | 1 |
| Byington, RP; Crouse, JR; Espeland, MA; Furberg, CD | 1 |
| Hanaki, Y; Ohno, M; Ozawa, T; Sugiyama, S | 1 |
| Bellandi, F; Cantini, F; Palchetti, R; Pedone, T | 1 |
| Manns, MP; Schmidt, HH; Wagner, S | 1 |
| Giraldez, RR; Mansur, AP; Maranhão, RC; Pileggi, F; Ramires, JA; Safi Júnior, J; Santos, RD | 1 |
| Rogers, S | 1 |
| de Bono, DP; Samani, NJ | 1 |
| Davis, DR | 1 |
| Johnson, KH; Millard, P | 1 |
| Fey, R; Pearson, N | 1 |
| Windler, E | 1 |
| Holme, I | 1 |
| Olsson, AG | 2 |
| Davis, BR; Meyers, DG; Rouleau, JL; Sacks, FM; Wilt, TJ | 1 |
| Grimes, DS | 1 |
| Thompson, GR | 1 |
| Dash, C; Ekbom, T; Isacsson, A; Lindholm, LH; Scherstén, B | 1 |
| Pedersen, TR; Tobert, JA | 1 |
| Navarro, A | 1 |
| Diosy, A | 1 |
| Ashraf, T; Crouse, J; Davidson, M; Furberg, CD; Hay, JW; Pitt, B; Radican, L; Wittels, E | 1 |
| Klose, G | 1 |
| Blitz, A; Drinkwater, DC; Fonarow, G; Hage, A; Hamilton, MA; Kawata, N; Kobashigawa, JA; Laks, H; Moriguchi, JD | 1 |
| Arnold, JM; Braunwald, E; Brown, L; Cole, TG; Davis, BR; Moye, LA; Pfeffer, MA; Rouleau, JL; Rutherford, JD; Sacks, FM; Warnica, JW; Wun, CC | 1 |
| Clem, JR | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Gurr, E; Morris, R; Robinson, G; Tilyard, M | 1 |
| Northridge, D; Wright, R | 1 |
| Evéquoz, D | 1 |
| Rackley, CE | 1 |
| Simoons, ML | 1 |
| Fuchi, T; Fujita, T; Hachisuka, M; Inoue, T; Kinoshita, M; Morigami, N; Nakamura, Y; Shimakawa, H; Sugimoto, Y; Uchida, K; Ueshima, H; Yamaoka, O | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Brown, L; Cole, T; Davis, BR; Hawkins, CM; Moyé, LA; Sacks, F | 1 |
| Jackson, PR; Payne, JN; Pickin, DM; Ramsay, LE; Ul Haq, I; Yeo, WW | 1 |
| Grundy, SM | 2 |
| Force, R; Lawless, C | 1 |
| Haria, M; McTavish, D | 1 |
| Braesen, JH; Harsch, M; Niendorf, A | 1 |
| Sprecher, DL | 1 |
| Ettinger, WH; Hazzard, WR | 1 |
| Kuller, LH; Modan, B | 1 |
| Auerbach, I; Behar, S; Motro, M | 1 |
| Applegate, WB; Cushman, W; Elam, MB; Heimberg, M | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Bhatnagar, D | 1 |
| Corrigan, F | 1 |
| Muntoni, S | 1 |
| Poli, A | 1 |
| Agner, E; Leth, A; Mortensen, SA; Rohde, M | 1 |
| Bery, A; Halle, M; Keul, J | 1 |
| Berger, K; Klose, G; Szucs, TD | 1 |
| Donaldson, C; Glasziou, PP; Hall, J; Simes, RJ | 1 |
| Ito, MK; Shabetai, R | 1 |
| Bassand, JP; Bertrand, ME; Cassagnes, J; Castaigne, A; Commeau, P; Danchin, N; Fruchart, JC; Grollier, G; Lablanche, JM; Machecourt, J; McFadden, EP; Mossard, JM; Vacheron, A; Van Belle, E | 1 |
| Sussekov, AV | 1 |
| Zanchetti, A | 1 |
| Smith, SC | 2 |
| Assmann, G; Cullen, P | 1 |
| Kobashigawa, JA | 1 |
| Caro, J; Ford, I; Klittich, W; McGuire, A; McMurray, J; Norrie, J; Pettitt, D; Shepherd, J | 1 |
| Ellen, RL; McPherson, R | 1 |
| Kesäniemi, YA | 1 |
| Meyer, FP | 2 |
| Eisenberg, DA | 1 |
| Pharoah, P | 1 |
| Braunwald, E; Cole, TG; Davis, BR; Moyé, LA; Nash, DT; Pfeffer, MA; Rouleau, JL; Sacks, FM | 1 |
| Freemantle, N; Mason, J | 1 |
| Chia, D; Hirata, M; Katznelson, S; Kobashigawa, JA; Ozawa, M; Terasaki, PI; Wang, XM; Zhong, HP | 1 |
| Jax, TW; Leschke, M; Schoebel, FC; Strauer, BE | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Rosenson, RS; Tangney, CC | 1 |
| Mabuchi, H | 1 |
| Closon, MC; Muls, E; Van Ganse, E | 1 |
| Berger, K; Guggenberger, G; März, W; Schäfer, JR; Szucs, TD | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Otto, C; Schwandt, P | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| de Alcantara, ML; Kaiser, SE | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Hingorani, AD; Vallance, P | 1 |
| Pritzker, LB | 1 |
| Chua, TP; Fox, KM; Saia, F | 1 |
| Lindbloom, EJ | 1 |
| Scheen, AJ | 1 |
| März, W; Szucs, TD | 1 |
| Pitt, B | 1 |
| Coukell, AJ; Wilde, MI | 1 |
| Bloom, JM | 1 |
| Mahé, I | 1 |
| Ikewaki, K; Kaffarnik, H; Maisch, B; Schaefer, JR; Schweer, H; Seyberth, HJ; Steinmetz, A; Stracke, H | 1 |
| Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Stolley, SN | 1 |
| Waters, D | 1 |
| Cernacek, P; Dupuis, J; Tardif, JC; Théroux, P | 1 |
| Lim, PO; Yee, KM | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Linderer, T; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Goodwin, L | 1 |
| Menotti, A; Poli, A | 1 |
| Ryan, EW; Tonkin, AM | 1 |
| Velasco, JA | 1 |
| Feely, J | 1 |
| Gallardo, F; Gomez, MV; Gonzalez-Maqueda, I; Martín-Jadraque, L; Martín-Jadraque, R; Mostaza, JM; Plaza-Celemín, L; Salazar, ML | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Johnson, RA | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Babu, BR; Belew, K; Cohen, JD; Donohue, T; Drury, JH; Finn, J; Flaker, G; Labovitz, A; Ostdiek, J | 1 |
| Cesar, LA; Maranhão, RC; Ramires, JA; Santos, RD; Sposito, AC; Ventura, LI | 1 |
| Goldman, L; Goldman, PA; Hunink, MG; Prosser, LA; Stinnett, AA; Weinstein, MC; Williams, LW | 1 |
| Aboyoun, C; Kaan, A; Keogh, A; Macdonald, P; Mundy, J; Spratt, P | 1 |
| Haffner, SM | 2 |
| Roberts, CS | 1 |
| Cozma, LS; Ogunko, A; Rees, A | 1 |
| Anderson, NE; Colquhoun, DM; Glasziou, P; Hankey, GJ; Hunt, D; Kirby, AC; MacMahon, S; Simes, RJ; Tonkin, AM; Watson, JD; West, MJ; White, HD | 1 |
| Ridker, PM | 1 |
| Fruchart, JC | 1 |
| Berger, K; März, W; Schäfer, JR; Szucs, TD | 1 |
| Bal, ET; Bruschke, AV; Jukema, JW; Mulder, HJ; Schalij, MJ; van Boven, AJ; Zwinderman, AH | 1 |
| Braunwald, E; Byington, R; Cobbe, S; Furberg, CD; Hawkins, CM; Keech, A; Packard, C; Sacks, FM; Shepherd, J; Simes, J; Tonkin, AM | 1 |
| Caslake, MJ; Cooney, J; Ford, I; Krishna, M; Lowe, GD; Macphee, CH; McMahon, AD; O'Reilly, DS; Packard, CJ; Rumley, A; Suckling, KE; Wilkinson, FE | 1 |
| Browner, WS; Grady, D; Hulley, SB | 1 |
| Caro, JJ; Closon, MC; De Backer, G; De Bacquer, D; Huybrechts, KF | 1 |
| Durrington, P | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Brett, AS | 1 |
| Davidson, MH | 1 |
| Cheng, JW; Sotiriou, CG | 1 |
| Plutzky, J; Ridker, PM | 1 |
| Cobbe, SM; Ford, I; Freeman, DJ; Gaw, A; Isles, C; Lorimer, AR; Macfarlane, PW; McKillop, JH; Neely, RD; Norrie, J; Packard, CJ; Sattar, N; Shepherd, J | 1 |
| Baker, J; Byington, RP; Cobbe, SM; Davis, BR; Plehn, JF; Shepherd, J; White, HD | 1 |
| Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT | 1 |
| Rifai, N; Yu, H | 1 |
| Dunlay, R; Koch, M; Lund, RJ; Meares, AJ; Oldemeyer, JB | 1 |
| Crouch, MA | 1 |
| Baker, J; Emberson, J; Hague, W; Hunt, D; MacMahon, S; Reid, IR; Sharpe, N; Tonkin, A | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; O'Malley, PG; Taylor, AJ | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME | 1 |
| Furutani, N; Tada, N | 1 |
| Homma, Y | 1 |
| Oida, K | 1 |
| Ouchi, Y | 1 |
| Hague, W; Hunt, D; Lane, G; Mann, S; Owensby, D; Simes, J; Tonkin, A; Young, P | 1 |
| Azar, RR; Waters, DD | 1 |
| Albert, MA; Chew, P; Ridker, PM; Staggers, J | 1 |
| Ausiello, JC; Chaisson, CE; Stafford, RS; Wang, TJ | 1 |
| Waters, DD | 1 |
| Comaschi, MA; Menozzi, F | 1 |
| Maclaine, GD; Patel, H | 1 |
| Reynolds, TM; Wierzbicki, AS | 1 |
| De Gevigney, G; Delahaye, F | 1 |
| Houghton, JL | 1 |
| Colquhoun, D; Friedlander, D; Glasziou, P; Harris, P; Marschner, IC; Simes, RJ; Singh, BB; Thompson, P; Tonkin, A; White, H | 1 |
| Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA | 1 |
| Aldridge, MA; Delucca, GM; Ito, MK | 1 |
| Dresselhaus, TR; Henry, RR; Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Shabetai, R | 1 |
| Campos, H; Glasser, SP; Moye, LA; Sacks, FM; Stampfer, MJ | 1 |
| Auer, J; Eber, B | 1 |
| Berryman, ER; Gregory, CR; Griffey, SM; Katznelson, S; Kyles, AE | 1 |
| Chou, TF; Lee, TM; Su, SF; Tsai, CH | 1 |
| Cesar, LA; Coelho, OR; Mansur, AP; Maranhão, M; Ramires, JA; Sposito, AC | 1 |
| Adelman, A | 1 |
| Werkö, L | 1 |
| Hsue, PY; Waters, DD | 1 |
| Liew, D; Lim, SS; McNeil, JJ; Peeters, A; Vos, T | 1 |
| Braunwald, E; Davis, BR; Ford, I; Furberg, CD; Shepherd, J; Simes, J; Tonkin, A | 1 |
| Colquhoun, D; Hague, W; Hunt, D; Keech, A; Marschner, IC; Shaw, J; Simes, RJ; Stewart, RA; Sullivan, D; Thompson, P; Tonkin, A; White, H | 1 |
| Stein, EA | 1 |
| Gaw, A | 1 |
| Braunwald, E; Craven, T; Furberg, CD; Keech, A; Pfeffer, MA; Sacks, FM; Shepherd, J; Tonkin, AM | 1 |
| Basso, F; Humphries, SE; Lowe, GD; McMahon, AD; Rumley, A | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Ehreth, J; Ford, I; Jackson, J; L'Italien, G; LaPuerta, P; Norrie, J; Shepherd, J | 1 |
| Alaupovic, P; Moye, LA; Sacks, FM | 1 |
| Cobbaert, C; Kesteloot, H; Meyns, B; Sergeant, P; Szécsi, J | 1 |
| Cobbaert, C; Kesteloot, H; Lesaffre, E; Meyns, B; Sergeant, P; Szécsi, J | 1 |
| Itakura, H | 1 |
| Barth, JD; Zonjee, MM | 1 |
| Armstrong, VW; Fieseler, HG; Schütz, E; Seidel, D; Thiery, J; Walli, AK; Wieland, E | 1 |
| Barrow, SE; Benjamin, N; Brassfield, T; Ritter, JM; Stratton, PD | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eriksson, M; Fager, G; Olofsson, SO; Wiklund, O | 1 |
| Bain, SC; Jones, AF; Lemon, M; Walker, MR | 1 |
| Arai, M; Fukami, M; Fukushige, J; Ito, T; Kuroda, M; Shiomi, M; Tamura, A; Tsujita, Y; Watanabe, Y | 1 |
73 review(s) available for pravastatin and Coronary Disease
| Article | Year |
|---|---|
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2007 |
Update on the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Assessment; Risk Factors | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Simvastatin | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
[Primary and secondary prevention of coronary disease by statins].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1999 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Sex Factors; Smoking; Stroke | 2004 |
Statins and secondary prevention of coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Survival Analysis; Treatment Outcome | 2004 |
Lessons learned from the prospective pravastatin pooling project.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipid Metabolism; Male; Middle Aged; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2004 |
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Chronic Disease; Comorbidity; Coronary Disease; Creatinine; Databases, Factual; Double-Blind Method; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Randomized Controlled Trials as Topic; Risk | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
Statins: can the new generation make an impression?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
Topics: Aged; Chronic Disease; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Models, Statistical; Pravastatin; Randomized Controlled Trials as Topic; Renal Insufficiency; Retrospective Studies; Risk | 2005 |
Optimal goals for statin use in patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Treatment Outcome | 2005 |
Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clinical Trials as Topic; Coronary Disease; Cytochrome P-450 CYP2C9; Genetic Testing; Genotype; Hemorrhage; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Warfarin | 2006 |
Pravastatin-induced lichenoid drug eruption.
Topics: Biopsy, Needle; Coronary Disease; Drug Eruptions; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lichenoid Eruptions; Middle Aged; Pravastatin; Severity of Illness Index | 2006 |
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome | 2006 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Initiating statins in the elderly: the evolving challenge.
Topics: Aged; Clinical Trials as Topic; Coronary Disease; Diabetic Angiopathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Safety; Stroke | 2008 |
Extending the benefit of lipid-regulating therapy to primary prevention.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic | 1995 |
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Topics: Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin | 1997 |
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Germany; Humans; National Health Programs; Pravastatin; Randomized Controlled Trials as Topic; Survival Rate | 1997 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors | 1997 |
Review of recent clinical trials of lipid lowering in coronary artery disease.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin; Simvastatin | 1997 |
Targeting nonalloimmune-dependent pathways.
Topics: Antihypertensive Agents; Coronary Artery Bypass; Coronary Disease; Diltiazem; Heart Transplantation; Humans; Hypertension; Immunosuppressive Agents; Photopheresis; Postoperative Complications; Pravastatin; Reoperation; Risk Factors | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Serum triglycerides and clinical benefit in lipid-lowering trials.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Myocardial Infarction; Myocardial Ischemia; Postmenopause; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin; Randomized Controlled Trials as Topic | 1998 |
Risk factor modification: rationale for management of dyslipidemia.
Topics: Anticholesteremic Agents; Canada; Controlled Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Pravastatin; Regression Analysis; Risk Factors; Scandinavian and Nordic Countries; United States | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Are there differences in various statins?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease].
Topics: Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin | 1998 |
Do lipid lowering drugs reduce the risk of coronary heart disease?
Topics: Angiography; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Coronary Artery Disease; Coronary Disease; Europe; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Survival Rate | 1998 |
[The new debate on cholesterol: is the lowest level the best?].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Guidelines as Topic; Humans; Hypercholesterolemia; Male; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin; Sweden | 1999 |
Results of recent trials on the progression of coronary artery disease and recurrent ischemic events: implications for interventional cardiology.
Topics: alpha-Linolenic Acid; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diet Therapy; Disease Progression; Humans; Myocardial Ischemia; Pravastatin | 1994 |
Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Humans; Lipids; Pravastatin | 1998 |
Statin trials and goals of cholesterol-lowering therapy after AMI.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Europe; Humans; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; United States | 1999 |
Decrease in all-cause and CHD mortality with pravastatin over a broad range of initial cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Coronary Disease; Humans; Middle Aged; New Zealand; Pravastatin; Randomized Controlled Trials as Topic; Risk | 1998 |
[Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Smoking; Time Factors | 1999 |
Prevention of mortality from coronary heart disease with pravastatin.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Humans; Pravastatin | 1999 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Topics: Blood Coagulation; Blood Platelets; Blood Pressure; Blood Viscosity; Cholesterol; Coronary Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth; Pravastatin; Simvastatin | 2000 |
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Male; Pravastatin; Proportional Hazards Models; Prospective Studies; Stroke; Time Factors | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
Statin therapy: where are we? Where do we go next?
Topics: Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[WOSCOPS [West of Scotland Coronary Prevention Study]].
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Scotland | 2001 |
[LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]].
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk; Time Factors; Treatment Outcome | 2001 |
[CARE[ Cholesterol and Recurrent Events Trial]].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2001 |
[PATE Study [Pravastatin anti-Atherosclerosis Trial in the Elderly Study]].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Risk | 2001 |
What do the statin trials tell us?
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Outcome Assessment, Health Care; Pravastatin; Stroke; United States | 2001 |
[Secondary prevention of coronary artery disease with lipid-lowering drugs].
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Morbidity; Myocardial Revascularization; Patient Selection; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Healthy ageing: addressing acute coronary syndrome?
Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Australia; Coronary Disease; Endothelium, Vascular; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; New Zealand; Pravastatin; Risk Factors; Sex Factors; Simvastatin; Syndrome; United States | 2001 |
Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs.
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
169 trial(s) available for pravastatin and Coronary Disease
| Article | Year |
|---|---|
Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Coronary Disease; Female; Humans; Male; Middle Aged; Pravastatin; Primary Prevention; Proportional Hazards Models; Survival Rate; Time Factors; Treatment Outcome | 2018 |
Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
Topics: Aged; Coronary Disease; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Prospective Studies; Renal Insufficiency, Chronic; Survival Rate; Time Factors; Treatment Outcome; United States | 2013 |
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
Topics: Aged; Anticholesteremic Agents; Black People; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Patient Compliance; Pravastatin; Risk Factors; Treatment Outcome | 2013 |
Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Topics: Aged; Aged, 80 and over; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Netherlands; Pravastatin; Prospective Studies | 2013 |
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Topics: Aged; Angina, Unstable; Australia; Biomarkers; Coronary Disease; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Up-Regulation | 2013 |
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic
Topics: Adult; Aged; Angina, Unstable; Biomarkers; C-Reactive Protein; Coronary Disease; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Pravastatin; Risk Assessment; Stroke; Troponin I | 2014 |
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pravastatin; Predictive Value of Tests; Time Factors | 2013 |
Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.
Topics: Aged; Aged, 80 and over; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Netherlands; Pravastatin; Prospective Studies; Scotland; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Topics: Adrenomedullin; Adult; Aged; Biomarkers; Coronary Disease; Female; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Pravastatin; Predictive Value of Tests; Prognosis; Protein Precursors; Recurrence; Risk Assessment | 2014 |
ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
Topics: Aged; Alleles; ATP Binding Cassette Transporter 1; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Genotype; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Polymorphism, Single Nucleotide; Pravastatin; Proportional Hazards Models; Stroke | 2014 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Renal Insufficiency, Chronic; Uric Acid | 2015 |
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study.
Topics: Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Recurrence; Risk; Stroke | 2009 |
Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cerebral Infarction; Cholesterol; Combined Modality Therapy; Coronary Disease; Diet; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Pravastatin; Severity of Illness Index | 2009 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease.
Topics: Adult; Aged; B7-2 Antigen; Cholesterol, LDL; Coronary Disease; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Innate; Male; Middle Aged; Pravastatin | 2009 |
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.
Topics: Aged; Blood Coagulation Factors; Coronary Disease; Drug Resistance; Female; Genetic Predisposition to Disease; Genotype; Humans; Hypertension; Hypolipidemic Agents; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Treatment Outcome | 2009 |
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial.
Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Desmosterol; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phytosterols; Pravastatin; Sitosterols; Triglycerides | 2010 |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2009 |
Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease.
Topics: Aged; Amino Acid Substitution; Arginine; Asian People; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Coronary Disease; Female; Gene Frequency; Genotype; Humans; Hypolipidemic Agents; Lipids; Lysine; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pravastatin; Treatment Outcome | 2009 |
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly.
Topics: Aged; Aged, 80 and over; Coronary Disease; Female; Genetic Loci; Genetic Predisposition to Disease; Genetic Variation; Humans; Lipoproteins; Male; Membrane Proteins; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Pravastatin; Risk; Treatment Outcome | 2010 |
Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).
Topics: Aged; Antihypertensive Agents; Black or African American; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Severity of Illness Index | 2009 |
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.
Topics: Age Factors; Aged; Coronary Disease; Double-Blind Method; Europe; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kinesins; Male; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Topics: Aged; Apolipoproteins; Belgium; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Poland; Pravastatin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Triglycerides | 2010 |
Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.
Topics: Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Pravastatin; ROC Curve | 2011 |
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation.
Topics: Body Mass Index; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Obesity; Poverty; Pravastatin; Risk Factors; Scotland | 2011 |
Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).
Topics: Adult; Age Factors; Aged; Asian People; Cardiovascular Diseases; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk Factors; Stroke | 2011 |
The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Combined Modality Therapy; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Primary Prevention | 2012 |
Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.
Topics: Aged; Coronary Disease; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin | 2012 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Association of factor VII levels with inflammatory parameters in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Blood Coagulation Tests; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Drug Administration Schedule; Factor VII; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Inflammation Mediators; Linear Models; Male; Middle Aged; Pravastatin; Probability; Reference Values; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2002 |
Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Topics: Adult; Aged; Anticholesteremic Agents; Cerebrovascular Disorders; Cholesterol, LDL; Coronary Disease; Female; Humans; Japan; Male; Middle Aged; Pravastatin; Treatment Outcome | 2002 |
Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Topics: Adolescent; Adult; Cholesterol, LDL; Coronary Disease; Female; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Survival Analysis; Treatment Outcome | 2002 |
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Pravastatin; Prognosis; Risk Factors; Stroke | 2002 |
Pravastatin promotes coronary collateral circulation in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Collateral Circulation; Coronary Circulation; Coronary Disease; Female; Humans; Male; Pravastatin | 2002 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
Topics: Aged; Anticholesteremic Agents; Cerebral Infarction; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Risk; Treatment Outcome | 2003 |
Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Time Factors | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors | 2003 |
Improvement of serum oxidation by pravastatin might be one of the mechanisms by which endothelial function in dilated coronary artery segments is ameliorated.
Topics: Acetylcholine; Adult; Aged; Anticholesteremic Agents; Blood; Coronary Disease; Coronary Vessels; Double-Blind Method; Endothelium, Vascular; Humans; In Vitro Techniques; Middle Aged; Oxidation-Reduction; Pravastatin; Vasodilation | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease Progression; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pravastatin; Statistics, Nonparametric | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
Topics: Abetalipoproteinemia; Anticholesteremic Agents; Biopsy; Carrier Proteins; Case-Control Studies; Cholesterol, LDL; Codon; Cohort Studies; Coronary Disease; Disease Susceptibility; Double-Blind Method; Genotype; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardium; Polymorphism, Genetic; Pravastatin; Promoter Regions, Genetic; Prospective Studies; Risk; RNA, Messenger; Scotland; Sweden | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
[Comparison of effects of taizhi' an capsule and pravastatin on vascular endothelial function in senile patients with coronary heart disease].
Topics: Aged; Angina Pectoris; Carotid Arteries; Coronary Disease; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelium, Vascular; Female; Humans; Male; Phytotherapy; Pravastatin; Ultrasonography | 2004 |
Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Case-Control Studies; Coronary Disease; Factor VII; Factor XIIa; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Incidence; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Predictive Value of Tests; Risk Factors; Scotland; Thrombophilia; Triglycerides | 2004 |
Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Blood Pressure; Body Mass Index; Coronary Disease; Diet; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Patient Selection; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors | 2004 |
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin | 2004 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
Topics: Aged; Biomarkers; Coronary Disease; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Pravastatin; Predictive Value of Tests; Prognosis; Stroke; Survival Rate | 2005 |
Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
Topics: Albuminuria; Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Female; Fosinopril; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Survival Analysis | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Pravastatin; Risk Factors; Smoking; Ultrasonography | 2005 |
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation | 2005 |
Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
Topics: Adult; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Elective Surgical Procedures; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Irbesartan; Mammary Arteries; Membrane Glycoproteins; Muscle, Smooth, Vascular; NADPH Oxidase 2; NADPH Oxidases; Natriuretic Peptide, C-Type; Nitric Oxide Synthase Type III; Oxidative Stress; Polymerase Chain Reaction; Pravastatin; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Scavenger Receptors, Class E; Tetrazoles | 2006 |
Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Neoplasms; Pravastatin; Proportional Hazards Models; Risk; Smoking | 2006 |
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics | 2007 |
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Risk Factors | 2007 |
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.
Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Cholesterol; Coronary Disease; Female; Genotype; Humans; Lipids; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Prospective Studies; Treatment Outcome | 2007 |
Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy.
Topics: Adolescent; Anticholesteremic Agents; Biomarkers; Child; Child, Preschool; Cholesterol, HDL; Colorimetry; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Graft Rejection; Heart Failure; Heart Transplantation; Humans; Infant; Male; Postoperative Complications; Pravastatin; Prospective Studies; Treatment Outcome; Ultracentrifugation | 2007 |
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2007 |
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pravastatin | 2007 |
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
Topics: Adult; Age Factors; Analysis of Variance; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Genetic Variation; Genotype; Humans; Male; Matrix Metalloproteinases; Middle Aged; Polymorphism, Genetic; Pravastatin; Predictive Value of Tests; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2008 |
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Treatment Outcome | 2008 |
[Long-term follow-up of the West of Scotland Coronary Prevention Study].
Topics: Cause of Death; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pravastatin; Retrospective Studies; Scotland; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Topics: Aged; Aged, 80 and over; Cholesterol, LDL; Coronary Disease; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linkage Disequilibrium; Male; Odds Ratio; Polymorphism, Single Nucleotide; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2008 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study.
Topics: Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Myocardial Infarction; Neoplasms; Pravastatin; Risk; Survival Analysis | 1995 |
[Limitation of atherosclerosis in coronary arteries with pravastatin (PLAC 1)].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Humans; Pravastatin; Time Factors | 1995 |
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Enzyme Inhibitors; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Scotland | 1995 |
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1995 |
Effect of pravastatin on outcomes after cardiac transplantation.
Topics: Cholesterol; Coronary Disease; Coronary Vessels; Cytotoxicity, Immunologic; Female; Graft Rejection; Heart Transplantation; Humans; Hypercholesterolemia; Incidence; Killer Cells, Natural; Male; Middle Aged; Pravastatin; Prospective Studies; Survival Rate; Ultrasonography, Interventional | 1995 |
Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
Topics: Age Factors; Cholesterol; Coronary Disease; Double-Blind Method; Humans; Male; Mass Screening; Middle Aged; Patient Selection; Pravastatin; Reference Values; Risk Factors; Scotland; Triglycerides | 1995 |
Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B.
Topics: Autoantibodies; Coronary Disease; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Pravastatin | 1995 |
Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate.
Topics: Aged; Angioplasty, Balloon, Coronary; Cholesterol; Coronary Disease; Female; Humans; Male; Middle Aged; Pravastatin | 1995 |
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Topics: Angioplasty, Balloon, Coronary; Cholesterol; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Humans; Lipids; Male; Middle Aged; Pravastatin; Reference Values | 1995 |
The RED-LIP study--pravastatin in primary isolated hypercholesterolemia--an open, prospective, multicenter trial.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; Triglycerides | 1994 |
[Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
Topics: Aged; Angioplasty, Balloon, Coronary; Cholesterol; Constriction, Pathologic; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Recurrence | 1995 |
The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Recurrence | 1994 |
Pravastatin, lipids, and major coronary events.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Life Tables; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Survival Analysis; Triglycerides | 1994 |
[Cholesterol and vascular disease. Study of pravastatin ].
Topics: Adult; Aged; Cerebrovascular Disorders; Coronary Disease; Drug Evaluation; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin | 1993 |
Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group.
Topics: Adverse Drug Reaction Reporting Systems; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Medical Records Systems, Computerized; Middle Aged; Mortality; Myocardial Infarction; Neoplasms; Pravastatin; Prospective Studies; Risk Factors; Scotland | 1995 |
[Comparative study of gemfibrozil versus pravastatin in the treatment of patients with coronary artery disease and low HDL cholesterol levels].
Topics: Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Pravastatin | 1995 |
Cholesterol-lowering agent in men without CHD.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Reproducibility of Results; Scotland; Survival Rate | 1996 |
[Statin therapy of individuals with high risk for coronary disease].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Male; Pravastatin; Risk Factors; Scotland; Simvastatin | 1996 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Coronary Disease; Cross-Sectional Studies; Female; Humans; Intracranial Arteriosclerosis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Prevalence; Recurrence; Risk Factors; Smoking | 1996 |
Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Female; Humans; Life Style; Male; Middle Aged; Patient Education as Topic; Pravastatin; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 1996 |
Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Vessels; Cytotoxicity, Immunologic; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Killer Cells, Natural; Male; Pravastatin; Prospective Studies | 1995 |
[Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Germany; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin; Scotland | 1996 |
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Survival Analysis; Treatment Outcome | 1996 |
Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Exercise Therapy; Feeding Behavior; Female; Humans; Hypercholesterolemia; Life Style; Male; Middle Aged; Placebos; Pravastatin; Risk Factors; Smoking Cessation; Triglycerides | 1996 |
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Risk; Scotland | 1996 |
Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol; Coronary Disease; Double-Blind Method; Female; Humans; Logistic Models; Male; Pravastatin; Prospective Studies; Recurrence | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Decision rules for predicting future lipid values in screening for a cholesterol reduction clinical trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost Control; Decision Support Techniques; Female; Humans; Hypercholesterolemia; Male; Mass Screening; Middle Aged; Multivariate Analysis; Normal Distribution; Patient Selection; Pravastatin; Randomized Controlled Trials as Topic; Sensitivity and Specificity | 1996 |
Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Probability; Risk Factors; Scotland; Time Factors; Treatment Outcome | 1997 |
A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
Topics: Aged; Anticholesteremic Agents; Clinical Protocols; Coronary Disease; Follow-Up Studies; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Random Allocation; Statistics as Topic | 1996 |
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Topics: Adult; Aged; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Risk Factors; Ubiquinone | 1997 |
Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
Topics: Absenteeism; Angina, Unstable; Anticholesteremic Agents; Australia; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Health Resources; Humans; Myocardial Infarction; New Zealand; Pravastatin; Quality-Adjusted Life Years; Recurrence; Research Design; Survival Analysis | 1997 |
Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Triglycerides | 1997 |
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Recurrence; Treatment Outcome | 1997 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors | 1997 |
Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Patient Dropouts; Pravastatin | 1997 |
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Scotland; Sensitivity and Specificity; Treatment Outcome | 1997 |
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Male; Middle Aged; Placebos; Pravastatin; Predictive Value of Tests; Risk Factors; Treatment Outcome; Triglycerides | 1998 |
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Recurrence; Risk Factors; Triglycerides | 1998 |
The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Disease; Cyclosporine; Disease Progression; Drug Synergism; Female; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Incidence; Killer Cells, Natural; Male; Middle Aged; Pravastatin; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 1998 |
Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Topics: Anticholesteremic Agents; Belgium; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Forecasting; Humans; Life Expectancy; Male; Middle Aged; Models, Economic; Pravastatin; Risk Factors; Sensitivity and Specificity; United States | 1998 |
[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Topics: Aged; Aged, 80 and over; Cholesterol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; National Health Programs; Pravastatin; Retrospective Studies | 1998 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pravastatin; Risk | 1998 |
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"].
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin | 1999 |
The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Follow-Up Studies; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Patient Admission; Pravastatin; Primary Health Care; Prospective Studies; Scotland | 1999 |
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Topics: Adult; Apolipoprotein A-I; Coronary Disease; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Pravastatin; Reference Values; Software; Statistics, Nonparametric; Treatment Outcome | 1999 |
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.
Topics: Anticholesteremic Agents; Blood Pressure; Brachial Artery; Cholesterol; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Endothelins; Endothelium, Vascular; Female; Heart Rate; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Stroke Volume; Syndrome; Ultrasonography; Vasodilation | 1999 |
Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Research Design; Risk Factors; Scotland | 1999 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels.
Topics: Aged; Cholesterol; Cholesterol, LDL; Coronary Circulation; Coronary Disease; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Male; Middle Aged; Pravastatin; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilation | 2000 |
Broader use of lipid-lowering therapy argued.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Folic Acid; Humans; Male; Middle Aged; Pravastatin; Pyridoxine; Risk Factors; Survival Analysis | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Triglycerides; Vasodilation | 2000 |
Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease.
Topics: Anticholesteremic Agents; Apolipoproteins B; Chylomicrons; Coronary Disease; Fat Emulsions, Intravenous; Female; Humans; Lipids; Lipolysis; Male; Metabolic Clearance Rate; Middle Aged; Pravastatin; Single-Blind Method | 2000 |
Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Middle Aged; Postoperative Care; Pravastatin; Safety; Simvastatin; Survival Rate; Treatment Outcome; Tunica Intima | 2000 |
Pravastatin therapy and the risk of stroke.
Topics: Adult; Aged; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Pravastatin; Risk Factors; Severity of Illness Index; Stroke | 2000 |
Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Placebos; Pravastatin; Prospective Studies; Risk Factors; Secondary Prevention | 2000 |
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Risk Factors; Treatment Outcome; Triglycerides | 2000 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemoprevention; Chi-Square Distribution; Cholesterol, LDL; Cholestyramine Resin; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Niacin; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Regression Analysis; Statistics, Nonparametric; Stroke; Survival Rate; Treatment Outcome | 2000 |
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Blood Glucose; Body Mass Index; Cohort Studies; Coronary Disease; Diabetes Mellitus; Humans; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prospective Studies; Risk Factors; Triglycerides | 2001 |
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Male; Pravastatin; Proportional Hazards Models; Prospective Studies; Stroke; Time Factors | 2001 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; Databases, Factual; Double-Blind Method; Doxazosin; Female; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Assessment; Survival Rate; Treatment Outcome; United States | 2001 |
Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease.
Topics: Aged; Anticholesteremic Agents; Bone and Bones; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoporosis; Pravastatin | 2001 |
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness.
Topics: Atorvastatin; Carotid Artery, Common; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Tunica Intima; Tunica Media | 2001 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cholesterol, Dietary; Cohort Studies; Coronary Disease; Double-Blind Method; Doxazosin; Ethnicity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lisinopril; Male; Middle Aged; Myocardial Infarction; Pravastatin; Racial Groups; Risk Factors; United States | 2001 |
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cause of Death; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors | 2001 |
Summaries for patients. Benefits of lowering cholesterol levels in older patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cause of Death; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors | 2001 |
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Topics: Adult; Anti-Inflammatory Agents; C-Reactive Protein; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Patient Selection; Pravastatin; Randomized Controlled Trials as Topic; Research Design | 2001 |
Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
Topics: Aged; Anticholesteremic Agents; Cerebral Infarction; Coronary Disease; Follow-Up Studies; Humans; Hypercholesterolemia; Japan; Lipids; Male; Middle Aged; Neoplasms; Patient Compliance; Pravastatin; Risk Factors | 2000 |
Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Syndrome | 2001 |
The effect of pravastatin and atorvastatin on coenzyme Q10.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone | 2001 |
Low-density lipoprotein size, pravastatin treatment, and coronary events.
Topics: Anticholesteremic Agents; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Humans; Logistic Models; Male; Middle Aged; Particle Size; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2001 |
Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine.
Topics: Adenosine; Aminophylline; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Disease; Electrocardiography; Female; Hemodynamics; Humans; Hyperlipidemias; Lactates; Male; Middle Aged; Myocardial Ischemia; Pravastatin | 2001 |
Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Angiography; Coronary Disease; Exercise Test; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pravastatin; Simvastatin | 2001 |
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
Topics: Aged; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prevalence; Risk Factors; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.
Topics: Adult; Aged; Australia; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; New Zealand; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides; United States | 2002 |
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
Topics: Anticholesteremic Agents; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fibrinogen; Homozygote; Humans; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Pravastatin | 2002 |
Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins.
Topics: Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Coronary Disease; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 2002 |
Time course of serum Lp(a) in men after coronary artery bypass grafting.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Humans; Lipoprotein(a); Male; Middle Aged; Postoperative Care; Pravastatin; Time Factors | 1992 |
Time course of serum lipid and lipoprotein levels after coronary bypass surgery: modification by pravastatin.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Humans; Lipids; Male; Middle Aged; Postoperative Care; Pravastatin; Time Factors | 1992 |
Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. The REGRESS Research Group.
Topics: Aged; Angioplasty, Balloon, Coronary; Cholesterol, HDL; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Netherlands; Pravastatin; Prospective Studies; Research Design; Surveys and Questionnaires | 1992 |
A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
Topics: Cholesterol; Coronary Disease; Double-Blind Method; Electrocardiography; Health Education; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Scotland | 1992 |
Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Naphthalenes; Platelet Activation; Pravastatin; Risk Factors; Thromboxane B2 | 1991 |
179 other study(ies) available for pravastatin and Coronary Disease
| Article | Year |
|---|---|
D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study.
Topics: Adult; Aged; Biomarkers; Coronary Disease; Female; Fibrin Fibrinogen Degradation Products; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasms; Pravastatin; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Venous Thromboembolism | 2018 |
Aortic superoxide production at the early hyperglycemic stage in a rat type 2 diabetes model and the effects of pravastatin.
Topics: Animals; Aorta; Blood Glucose; Catalase; Coronary Disease; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelium, Vascular; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase Type III; Pravastatin; Protein Kinase C; Rats, Long-Evans; Superoxides | 2014 |
Estimation of controlled direct effects in time-varying treatments using structural nested mean models: application to a primary prevention trial for coronary events with pravastatin.
Topics: Adult; Aged; Biostatistics; Cholesterol; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Models, Statistical; Pravastatin; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Regression Analysis | 2014 |
A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
Topics: Biomarkers; Biostatistics; Computer Simulation; Coronary Disease; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon alpha-2; Interferon-alpha; Lipids; Macular Degeneration; Models, Statistical; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2014 |
Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Risk Assessment; Simvastatin | 2015 |
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.
Topics: Adult; Aged; Apolipoprotein C-III; Atorvastatin; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Regression Discontinuity Design: Simulation and Application in Two Cardiovascular Trials with Continuous Outcomes.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Cholesterol; Computer Simulation; Coronary Disease; Dementia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Monte Carlo Method; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Research Design; Risk Reduction Behavior; Statistics as Topic | 2016 |
Letter by Koh Regarding Article, "Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: 16 Years of Follow-Up of the LIPID Study".
Topics: Anticholesteremic Agents; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin | 2016 |
The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia.
Topics: Adult; Alcohol Drinking; Cholesterol, HDL; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pravastatin; Risk Assessment; Risk Factors; Smoking | 2008 |
Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Risk Factors; Triglycerides | 2010 |
Efficacy and safety of more intensive lowering of LDL cholesterol.
Topics: Age Factors; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Meta-Analysis as Topic; Neoplasms; Odds Ratio; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2011 |
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Statin therapy in the elderly: might there be uncertainty in the majority?
Topics: Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Polymorphism, Genetic; Pravastatin | 2012 |
Statin-induced myopathy in a patient with previous poliomyelitis.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Postpoliomyelitis Syndrome; Pravastatin | 2013 |
The extent of late in-stent neointima formation is modified by treatment with pravastatin: a preliminary study with intravascular ultrasound.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Risk Factors; Stents; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2002 |
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Risk Factors; Treatment Outcome | 2002 |
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pravastatin; Severity of Illness Index | 2002 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
The PROSPER trial.
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Disease; Humans; Incidence; Killer Cells, Natural; Neoplasms; Patient Selection; Pravastatin | 2003 |
Statin fails to meet expectations.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Treatment Failure | 2003 |
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
Topics: Apolipoprotein C-III; Apolipoproteins C; Case-Control Studies; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prospective Studies; Recurrence; Risk; Risk Factors; Triglycerides | 2003 |
[Statin treatment in type 2 diabetes. Is it a must today?].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Life Style; Middle Aged; Placebos; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2003 |
More on PROSPER.
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
More on PROSPER.
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Topics: Coronary Disease; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Simvastatin | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Topics: Body Mass Index; C-Reactive Protein; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus; Follow-Up Studies; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Obesity; Pravastatin; Predictive Value of Tests; Risk Assessment; Scotland; Triglycerides | 2003 |
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome | 2003 |
A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Genotype; Glycoproteins; Homozygote; Humans; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pravastatin; Risk Factors; Scotland; Smoking | 2003 |
Preventing the next event in the elderly: the PROSPER perspective.
Topics: Aged; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin.
Topics: Adult; Anticholesteremic Agents; Child; Cholesterol; Cohort Studies; Coronary Disease; Female; Heart Transplantation; Humans; Hypercholesterolemia; Immunosuppressive Agents; Male; Postoperative Complications; Pravastatin; Prevalence; Retrospective Studies; Risk Factors; Triglycerides | 2004 |
Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 2004 |
Believe-it then PROVE-IT.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values | 2004 |
Battle of the statins, or how the news media can change patient care.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Updated guidelines support even lower cholesterol levels for at-risk patients.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States | 2004 |
Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Androstadienes; Animals; Cardiotonic Agents; Chromones; Coronary Disease; Dogs; Dose-Response Relationship, Drug; Enzyme Activation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pravastatin; Pyridines; Quinolines; Signal Transduction; Theophylline; Wortmannin | 2004 |
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles | 2004 |
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995.
Topics: Coronary Disease; History, 20th Century; Humans; Hypercholesterolemia; Male; Pravastatin | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2004 |
Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Cholesterol; Combined Modality Therapy; Coronary Disease; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Male; Multivariate Analysis; Postoperative Complications; Pravastatin; Retrospective Studies; Transplantation, Homologous; Treatment Outcome | 2005 |
PROVE IT then believe it.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2005 |
Metabolic syndrome criteria: ready for clinical prime time or work in progress?
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic | 2005 |
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein
Topics: Acute Disease; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Disease; Follow-Up Studies; Humans; Michigan; Phenalenes; Pravastatin; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Letter regarding article by Tonelli et al, "effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease".
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Kidney Diseases; Pravastatin; Risk Factors | 2006 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
[For coronary disease patients is certain: the lower the LDL the better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 2006 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Topics: Alleles; Anticholesteremic Agents; Antigens, CD; Asparagine; Aspartic Acid; Coronary Disease; Genetic Predisposition to Disease; Genotype; Humans; Male; Myocardial Infarction; Odds Ratio; Polymorphism, Single Nucleotide; Pravastatin; Receptors, Fc; Risk Factors; Scotland | 2006 |
Japan: are statins still good for everybody?
Topics: Anticholesteremic Agents; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors | 2006 |
Impact of high dose statin trials on hospital prescribers.
Topics: Aged; Atorvastatin; Cohort Studies; Coronary Disease; Databases, Factual; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Patient Discharge; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
Topics: Aged; Antihypertensive Agents; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment | 2007 |
Can telomere length predict cardiovascular risk?
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Male; Pravastatin; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Telomere; Telomere-Binding Proteins | 2007 |
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study.
Topics: Aging; Blood Pressure; Case-Control Studies; Cholesterol; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymerase Chain Reaction; Pravastatin; Risk Factors; Scotland; Telomere | 2007 |
Statins and renal function. Is the compound and dose making a difference?
Topics: Coronary Disease; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Pravastatin; Treatment Outcome | 2007 |
Statin therapy and the elderly: SAGE advice?
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study).
Topics: Aged; Anticholesteremic Agents; Computer Simulation; Confounding Factors, Epidemiologic; Coronary Disease; Data Interpretation, Statistical; Female; Humans; Male; Middle Aged; Models, Statistical; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Refusal | 2008 |
Primary prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin; Primary Prevention | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Diabetes Mellitus; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin | 2008 |
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lymphoma; Pravastatin | 2008 |
Long-term follow-up of the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Coronary Disease; Data Interpretation, Statistical; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin | 2008 |
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
Topics: Anticholesteremic Agents; Case-Control Studies; Coronary Disease; Female; Gene Frequency; Genotype; Humans; Kinesins; Logistic Models; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Pravastatin; Proportional Hazards Models; Prospective Studies; Risk Factors; Treatment Outcome | 2008 |
'Real-life' reduction in cholesterol with statins, 1993 to 2002.
Topics: Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Patient Compliance; Pravastatin; Scotland; Simvastatin; Treatment Outcome | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Statins prevent coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1995 |
Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Research Design | 1995 |
Lowering cholesterol with drugs and diet.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Male; Pravastatin; Sitosterols | 1995 |
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
Topics: Animals; Anticholesteremic Agents; Aorta; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Risk Factors; Swine; Thrombosis; Time Factors; Tunica Media | 1995 |
Recent advances in cardiac transplantation.
Topics: Coronary Disease; Cost Savings; Heart Transplantation; Humans; Ketoconazole; Mycoses; Pravastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Regression of transplant coronary artery disease during chronic HELP therapy: a case study.
Topics: Arteriosclerosis; Chemical Precipitation; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Extracorporeal Circulation; Fibrinogen; Follow-Up Studies; Heart Transplantation; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Pravastatin; Time Factors | 1995 |
Effects of lovastatin and pravastatin on coronary artery disease.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic | 1994 |
Coenzyme Q10 and coronary artery disease.
Topics: Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Pravastatin; Ubiquinone | 1993 |
Elevated lipoprotein(a) is lowered by a cholesterol synthesis inhibitor in a normocholesterolaemic patient with premature myocardial infarction.
Topics: Adult; Angiography; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Humans; Lipoprotein(a); Male; Myocardial Infarction; Pravastatin; Receptors, LDL; Up-Regulation | 1993 |
Prevention of coronary heart disease with pravastatin.
Topics: Anticholesteremic Agents; Coronary Disease; Drug Costs; Female; Humans; Hypercholesterolemia; Male; Pravastatin | 1996 |
Prevention of coronary heart disease with pravastatin.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Male; Pravastatin; Survival Analysis | 1996 |
Prevention of coronary heart disease with pravastatin.
Topics: Age Factors; Anticholesteremic Agents; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Sex Factors | 1996 |
Statins and coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors | 1996 |
[HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality].
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Survival Rate; Treatment Outcome | 1996 |
Statins and coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Humans; Male; Middle Aged; Pravastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
[Effect of pharmacological interventions on progression of coronary atherosclerosis].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Pravastatin; Primary Prevention; Risk Factors | 1996 |
Clinical significance of pravastatin study results.
Topics: Coronary Disease; Humans; Male; Myocardial Infarction; Pravastatin | 1996 |
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Chemoprevention; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Hospitalization; Humans; Life Expectancy; Life Tables; Male; Markov Chains; Middle Aged; Myocardial Infarction; Placebos; Pravastatin; Risk Factors; Treatment Outcome; Value of Life | 1996 |
The University of California at Los Angeles experience in heart transplantation.
Topics: Academic Medical Centers; Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Coronary Disease; Female; Graft Rejection; Heart Transplantation; Humans; Immunosuppression Therapy; Infant; Infant, Newborn; Infections; Los Angeles; Male; Middle Aged; Patient Selection; Pravastatin; Survival Rate; Tissue Donors | 1995 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
[Prevention of coronary disease using pravastatin in men with hyperlipidemia].
Topics: Coronary Disease; Humans; Hyperlipidemias; Male; Pravastatin | 1996 |
Interpretation of trials with drugs and devices; a double standard?
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Scotland; Survival Rate; Treatment Outcome | 1996 |
Lipid-lowering for prevention of coronary heart disease: what policy now?
Topics: Adult; Age Factors; Aged; Cholesterol; Coronary Disease; Costs and Cost Analysis; Female; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Risk; Simvastatin; United Kingdom | 1996 |
More on pravastatin and coronary disease.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Hypercholesterolemia; Pravastatin | 1996 |
Lipid lowering in post-MI patients with normal cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Sex Factors; Treatment Outcome | 1997 |
Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Coronary Disease; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Heterozygote; Hyperlipidemias; Male; Pravastatin; Rabbits; Time Factors | 1997 |
Lipid-lowering therapy for average lipid levels: the CARE trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1997 |
The effect of pravastatin on coronary events after myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Humans; Myocardial Infarction; Pravastatin; Risk | 1997 |
The effect of pravastatin on coronary events after myocardial infarction.
Topics: Breast Neoplasms; Coronary Disease; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Pravastatin | 1997 |
The effect of pravastatin on coronary events after myocardial infarction.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Myocardial Infarction; Pravastatin; Survival Analysis; Time Factors | 1997 |
Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Enzyme Inhibitors; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Morbidity; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Lipid-lowering drugs and mortality.
Topics: Cholestyramine Resin; Coronary Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Pravastatin; Treatment Outcome | 1997 |
Cholesterol-lowering drugs for primary prevention? The WOSCOP Study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland | 1997 |
Cholesterol and coronary heart disease: new data from the WOSCOP Study.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Randomized Controlled Trials as Topic; Scotland | 1997 |
Reduction of coronary events by pravastatin--is lowering low-density lipoprotein cholesterol the answer?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Pravastatin; Predictive Value of Tests | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1997 |
Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Plasmapheresis; Pravastatin; Regression Analysis; Risk Factors; Simvastatin | 1997 |
No primary prevention by pravastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Humans; Pravastatin | 1998 |
Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Models, Economic; Pravastatin | 1998 |
Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Data Collection; Humans; Pravastatin | 1998 |
Functional evaluation of lipid-lowering therapy by pravastatin.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol, LDL; Cohort Studies; Coronary Circulation; Coronary Disease; Drug Evaluation; Electrocardiography; Endothelium, Vascular; Exercise Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 1998 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
[Coronary mortality lowered by 24%. Convincing results of the LIPID Study on Secondary Prevention].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Myocardial Ischemia; Pravastatin | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Scotland | 1998 |
A simple computer program for guiding management of cardiovascular risk factors and prescribing.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Coronary Disease; Female; Humans; Male; Myocardial Infarction; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pravastatin; Risk Assessment; Risk Factors; Smoking; Software | 1999 |
The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Cohort Studies; Coronary Angiography; Coronary Disease; Data Interpretation, Statistical; Diabetes Complications; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Smoking; Treatment Outcome | 1998 |
Treating average cholesterol levels in patients with coronary heart disease.
Topics: Adult; Aged; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Treatment Outcome | 1999 |
Cost effectiveness of coronary prevention.
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Humans; Pravastatin; Primary Prevention; United Kingdom | 1999 |
Primary prevention.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Humans; Male; Managed Care Programs; Pravastatin; Primary Prevention; Risk Assessment; Scotland; United States | 1998 |
Secondary prevention.
Topics: Anticholesteremic Agents; Canada; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Humans; Managed Care Programs; Pravastatin; Scotland; United States | 1998 |
Pravastatin and coronary heart disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Treatment Outcome | 1999 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin | 1999 |
[What is the role of pravastatin in the secondary prevention of coronary disease?].
Topics: Adult; Aged; Angina, Unstable; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence | 1999 |
Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
Topics: Aged; Anticholesteremic Agents; California; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Health Planning; Hospitals, Veterans; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Simvastatin | 1999 |
Cholesterol lowering. Should it continue to be the last thing we do?
Topics: Anticholesteremic Agents; Blood Platelets; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Administration Schedule; Endothelium, Vascular; Humans; Hypercholesterolemia; Pravastatin; Vasodilation | 1999 |
After 4S, CARE and LIPID--is evidence-based medicine being practised?
Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Humans; Hypercholesterolemia; Pravastatin; Risk Factors; Simvastatin | 1999 |
The therapeutic gap--compliance with medication and guidelines.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Evidence-Based Medicine; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pravastatin | 1999 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Computer Simulation; Coronary Disease; Cost of Illness; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Sex Factors; Simvastatin | 2000 |
Secondary prevention of coronary heart disease: the role of fibric acids.
Topics: Anticholesteremic Agents; Clofibrate; Coronary Disease; Humans; Pravastatin | 2000 |
Postoperative drug therapy to extend survival after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Female; Humans; Male; Postoperative Care; Pravastatin; Survival Rate | 2000 |
Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Medical Audit; Myocardial Infarction; Pravastatin; Treatment Outcome | 2000 |
Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation.
Topics: C-Reactive Protein; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic | 2000 |
A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Pravastatin | 2000 |
[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Topics: Angina, Unstable; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Pravastatin; Quality of Life | 2000 |
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Coronary Disease; Fibrinogen; Humans; Hypercholesterolemia; Inflammation; Leukocyte Count; Logistic Models; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Risk Factors; Triglycerides | 2000 |
Statins: underused by those who would benefit.
Topics: Age Factors; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Humans; Hypolipidemic Agents; Legislation, Drug; Lovastatin; Nonprescription Drugs; Pravastatin; Self Medication; United States | 2000 |
Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Belgium; Coronary Disease; Cost-Benefit Analysis; Humans; Male; Middle Aged; Monte Carlo Method; Multivariate Analysis; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Risk; Risk Factors; Scotland | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Pravastatin therapy and the risk of stroke.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Pravastatin; Risk Factors; Stroke | 2000 |
Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Finland; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Life Style; Male; Metformin; Pravastatin; Risk Factors; Scotland | 2001 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pravastatin; Risk Factors; Simvastatin; Stroke | 2001 |
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Factors | 2000 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Rhabdomyolysis; Simvastatin | 2000 |
Statins early in acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Treatment Outcome | 2000 |
PRINCE's prospects: statins, inflammation, and coronary risk.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; Inflammation; Pravastatin | 2001 |
Randomized clinical trials and recent patterns in the use of statins.
Topics: Aged; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Female; Health Surveys; Humans; Hypercholesterolemia; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; United States | 2001 |
[Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].
Topics: Coronary Disease; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Scotland | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Statins and fractures.
Topics: Aged; Animals; Bone Density; Coronary Disease; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Pravastatin; Randomized Controlled Trials as Topic; Rats | 2001 |
Effect of cholesterol-lowering therapy on endothelial function.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Circulation; Coronary Disease; Endothelium, Vascular; Humans; Hypercholesterolemia; Infusions, Intra-Arterial; Microcirculation; Pravastatin; Simvastatin; Vascular Resistance; Vasomotor System | 2001 |
The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Cohort Studies; Coronary Disease; Disease-Free Survival; Female; Humans; Male; Pravastatin; Simvastatin; Statistics as Topic | 2001 |
Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol.
Topics: Aged; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Risk Factors; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts.
Topics: Animals; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endocardium; Everolimus; Fatty Acids, Monounsaturated; Fluvastatin; Heart Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Male; Monocytes; Myocardium; Pravastatin; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus | 2001 |
Statins in acute coronary syndromes: from bench to bedside.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Pravastatin | 2001 |
In patients with heart disease, is the benefit of lipid-lowering therapy with statins similar in older patients to that in younger patients?
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cause of Death; Coronary Disease; Evidence-Based Medicine; Humans; Hypercholesterolemia; Middle Aged; Patient Selection; Pravastatin; Risk Factors; Treatment Outcome | 2001 |
[Can the action of statins reveal etiology of coronary diseases?].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Pravastatin; Randomized Controlled Trials as Topic | 2001 |
Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2001 |
Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Topics: Adult; Aged; Aged, 80 and over; Australia; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance, Pharmaceutical Services; Male; Middle Aged; Models, Econometric; Monte Carlo Method; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2001 |
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endpoint Determination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Risk Factors; Time; Treatment Outcome; Triglycerides | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
Topics: Age Factors; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Scotland | 2000 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dietary Fiber; Energy Intake; Female; Humans; Hyperlipidemias; Male; Niceritrol; Pravastatin; Probucol | 1992 |
Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Pravastatin; Triglycerides | 1991 |
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Cholestyramine Resin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL | 1990 |
Apolipoprotein(a) and ischaemic heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins A; Coronary Disease; Heptanoic Acids; Humans; Liver; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Coronary Disease; Heptanoic Acids; Naphthalenes; Phospholipids; Pravastatin; Rabbits; Triglycerides; Xanthomatosis | 1990 |